Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 674219, 12 pages
http://dx.doi.org/10.1155/2014/674219
Research Article

Astragalus Polysaccharide Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the PI3k/Akt and p38MAPK Pathways

1The Fifth Clinical Hospital of Peking University, Health Science Center, Beijing 100730, China
2Key Laboratory of Geriatrics, Beijing Hospital, Beijing Institute of Geriatrics, Ministry of Health of China, Beijing 100730, China
3Capital Medical University Affiliated Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China

Received 9 July 2014; Accepted 11 September 2014; Published 16 October 2014

Academic Editor: Qingping Feng

Copyright © 2014 Yuan Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Zhu, M. H. Soonpaa, H. Chen et al., “Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway,” Circulation, vol. 119, no. 1, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Lipshultz, J. A. Alvarez, and R. E. Scully, “Anthracycline associated cardiotoxicity in survivors of childhood cancer,” Heart, vol. 94, no. 4, pp. 525–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. E. Ashour, M. M. Sayed-Ahmed, A. R. Abd-Allah et al., “Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 434195, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Zhang, X. Liu, T. Bawa-Khalfe et al., “Identification of the molecular basis of doxorubicin-induced cardiotoxicity,” Nature Medicine, vol. 18, no. 11, pp. 1639–1642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Zhou, A. Starkov, M. K. Froberg, R. L. Leino, and K. B. Wallace, “Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin,” Cancer Research, vol. 61, no. 2, pp. 771–777, 2001. View at Google Scholar · View at Scopus
  6. Y. Zhang, P. Shi, H. Yao, Q. Shao, and X. Fan, “Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen Yiqi Pills) in rat,” Current Drug Metabolism, vol. 13, no. 5, pp. 510–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Y.-P. Zhu, T. Shen, Y.-J. Lin et al., “Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-α-treated human vascular endothelial cells by blocking NF-κB activation,” Acta Pharmacologica Sinica, vol. 34, no. 8, pp. 1036–1042, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Liu, J. Qin, Y. Hao, J. Luo, T. Luo, and L. Wei, “Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: involvement of ROS-ERK and NF-κB pathways,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 782497, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Q.-Y. Liu, Y.-M. Yao, S.-W. Zhang, and Z.-Y. Sheng, “Astragalus polysaccharides regulate T cell-mediated immunity via CD11c highCD45RB low DCs in vitro,” Journal of Ethnopharmacology, vol. 136, no. 3, pp. 457–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. H. Chaanine and R. J. Hajjar, “AKT signalling in the failing heart,” European Journal of Heart Failure, vol. 13, no. 8, pp. 825–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Pacher, L. Liaudet, P. Bai et al., “Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction,” Circulation, vol. 107, no. 6, pp. 896–904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Zou, X.-Q. Mao, N. Wang, J. Liu, and J.-P. Ou-Yang, “Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK,” Acta Pharmacologica Sinica, vol. 30, no. 12, pp. 1607–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Shen, I. Aneas, N. Sakabe et al., “Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function,” Journal of Clinical Investigation, vol. 121, no. 12, pp. 4640–4654, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. U. T. Opfermann, A. A. Peivandi, M. Dahm et al., “Postoperative patterns and kinetics of cTnI, cTnT, CK-MB-activity and CK-activity after elective aortic valve replacement,” Swiss Medical Weekly, vol. 131, no. 37-38, pp. 550–555, 2001. View at Google Scholar · View at Scopus
  15. H.-N. Huang, P.-J. Lu, W.-C. Lo, C.-H. Lin, M. Hsiao, and C.-J. Tseng, “In situ Akt phosphorylation in the nucleus tractus solitarii is involved in central control of blood pressure and heart rate,” Circulation, vol. 110, no. 16, pp. 2476–2483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Li, R. Y. T. Sung, Z. H. Wei et al., “Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin,” Circulation, vol. 113, no. 18, pp. 2211–2220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Swain, F. S. Whaley, and M. S. Ewer, “Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials,” Cancer, vol. 97, no. 11, pp. 2869–2879, 2003. View at Google Scholar
  18. K. C. Nitiss and J. L. Nitiss, “Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage,” Clinical Cancer Research, vol. 20, no. 18, pp. 4737–4739, 2014. View at Publisher · View at Google Scholar
  19. J. Dudka, F. Burdan, A. Korga et al., “Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 139327, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. W. R. Bezwoda, R. Dansey, and L. Seymour, “High-dose 4′-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses,” Oncology, vol. 47, no. 1, pp. 4–8, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. P. W. Fisher, F. Salloum, A. Das, H. Hyder, and R. C. Kukreja, “Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity,” Circulation, vol. 111, no. 13, pp. 1601–1610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Y.-Y. Chan, P. Xiang, L. Zhou et al., “Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks,” European Journal of Heart Failure, vol. 13, no. 4, pp. 366–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Q.-Y. Liu, Y.-M. Yao, Y. Yu, N. Dong, and Z.-Y. Sheng, “Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4+CD25high T cells,” PLoS ONE, vol. 6, no. 6, Article ID e19811, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Basuray, B. French, B. Ky et al., “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes,” Circulation, vol. 129, no. 23, pp. 2380–2387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Walsh, “Akt signaling and growth of the heart,” Circulation, vol. 113, no. 17, pp. 2032–2034, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. L. Chen, X. D. Zhuang, Z. W. Xu et al., “Higenamine combined with [6]-gingerol suppresses doxorubicin-triggered oxidative stress and apoptosis in cardiomyocytes via upregulation of PI3K/Akt pathway,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 970490, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. S. Clark, K. West, S. Streicher, and P. A. Dennis, “Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells,” Molecular Cancer Therapeutics, vol. 1, no. 9, pp. 707–717, 2002. View at Google Scholar · View at Scopus
  28. T. Shen, M. Zheng, C. Cao et al., “Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis,” The Journal of Biological Chemistry, vol. 282, no. 32, pp. 23354–23361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Guo, K. Wu, J. Chen et al., “Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells,” Cellular Physiology and Biochemistry, vol. 32, no. 6, pp. 1668–1680, 2013. View at Publisher · View at Google Scholar · View at Scopus